← All trials
NCT05530954
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2022
- Primary completion
- May 31, 2023
- Completion date
- Jun 30, 2023
- First posted
- Sep 7, 2022
- Last posted
- Sep 7, 2022
- Enrollment
- 52
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Mansoura UniversityLead sponsor
- Mansoura UniversityOverall official - principal investigator
- Mansoura UniversityReponsible party - principal investigator
- Mansoura UniversityStudy chair
- Mansoura UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.